Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer

被引：3
|
作者：
Zhu, Shenyu [1 ,2 ]
Wu, Rongqian [3 ]
Liu, Xiangjin [4 ]
Xie, Bin [5 ]
Xie, Chunfa [1 ,2 ]
Li, Shulin [1 ,2 ]
Wu, Zhicheng [1 ,2 ]
Zhang, Zuxiong [1 ,2 ]
Tang, Zhixian [1 ,2 ]
Gu, Liang [1 ,2 ]
机构：
[1] Gannan Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Ganzhou, Peoples R China
[2] Ganzhou Key Lab Brain Injury & Brain Protect, Ganzhou, Peoples R China
[3] Nanchang Univ, Gaoxin Hosp, Affiliated Hosp 1, Dept Endocrinol & Metab, Nanchang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Dept Thorac Surg, Jiangxi Med Coll, Nanchang, Jiangxi, Peoples R China
[5] Gannan Med Univ, Clin Med Coll 1, Ganzhou, Peoples R China
来源：
FUTURE ONCOLOGY | 2024年 / 20卷 / 29期
基金：
中国国家自然科学基金;
关键词：
circulating tumor DNA; effect monitoring; immunotherapy; minimal residual disease; non-small cell lung cancer; targeted therapy; CIRCULATING TUMOR DNA; MINIMAL RESIDUAL DISEASE; ADJUVANT CHEMOTHERAPY; RESECTABLE NSCLC; LIQUID BIOPSY; PLASMA; EGFR; IMMUNOTHERAPY; METHYLATION; VALIDATION;
D O I：
10.1080/14796694.2024.2376513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is one of the most common malignancies worldwide, with non-small cell lung cancer (NSCLC) being the most common type. As understanding of precise treatment options for NSCLC deepens, circulating tumor DNA (ctDNA) has emerged as a potential biomarker that has become a research hotspot and may represent a new approach for the individualized diagnosis and treatment of NSCLC. This article reviews the applications of ctDNA for the early screening of patients with NSCLC, guiding targeted therapy and immunotherapy, evaluating chemotherapy and postoperative efficacy, assessing prognosis and monitoring recurrence. With the in-depth study of the pathogenesis of NSCLC, plasma ctDNA may become an indispensable part of the precise treatment of NSCLC, which has great clinical application prospects.
引用
收藏
页码：2213 / 2224
页数：12
相关论文
共 50 条
  • [1] ctDNA detection in early stage non-small cell lung cancer
    Heider, Katrin
    Wan, Jonathan C.
    Gale, Davina
    Ruiz-Valdepenas, Andrea
    Mouliere, Florent
    Morris, James
    Qureshi, Nagmi R.
    Qian, Wendi
    Wulff, Jerome
    Demiris, Nikolaos
    Howarth, Karen
    Green, Emma
    Rundell, Viona
    Eisen, Tim
    Cooper, Wendy
    Smith, Christopher G.
    Massie, Charles
    Harden, Susan
    Rassl, Doris M.
    Rintoul, Robert C.
    Rosenfeld, Nitzan
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
    Gale, D.
    Heider, K.
    Ruiz-Valdepenas, A.
    Hackinger, S.
    Perry, M.
    Marsico, G.
    Rundell, V
    Wulff, J.
    Sharma, G.
    Knock, H.
    Castedo, J.
    Cooper, W.
    Zhao, H.
    Smith, C. G.
    Garg, S.
    Anand, S.
    Howarth, K.
    Gilligan, D.
    Harden, S., V
    Rassl, D. M.
    Rintoul, R. C.
    Rosenfeld, N.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 500 - 510
  • [3] Clinical factors and prognosis in non-small cell lung cancer
    Martins, SJ
    Pereira, JR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 453 - 457
  • [4] Diagnosis and Treatment for Early Stage Non-small Cell Lung Cancer Preface
    Jones, David R.
    Date, Hiroshi
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2020, 68 (07) : 659 - 659
  • [5] Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients
    Goebel, Cherylle
    Louden, Christopher L.
    Mckenna, Robert, Jr.
    Onugha, Osita
    Wachtel, Andrew
    Long, Thomas
    CANCER GENOMICS & PROTEOMICS, 2019, 16 (04) : 229 - 244
  • [6] Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
    Zeng, H.
    Dong, X.
    Tong, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S31 - S32
  • [7] Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer
    Tang, Yong
    Qiao, Guibin
    Xu, Enwu
    Xuan, Yiwen
    Liao, Ming
    Yin, Guilin
    ONCOTARGETS AND THERAPY, 2017, 10 : 4527 - 4534
  • [8] Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer
    Perez, EA
    CHEST, 1998, 114 (02) : 593 - 604
  • [9] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [10] Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients
    Remon, J.
    Mezquita, L.
    Planchard, D.
    Jovelet, C.
    Lacroix, L.
    Rouleau, E.
    Howarth, K.
    Plagnol, V.
    Morris, C.
    Green, E.
    Le Pechoux, C.
    Caramella, C.
    Adam, J.
    Besse, B.
    ANNALS OF ONCOLOGY, 2018, 29
12345